journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Cardiovascular Disease

journal
https://www.readbyqxmd.com/read/28198204/nanomedicine-applied-to-cardiovascular-diseases-latest-developments
#1
Virna Margarita Martín Giménez, Diego E Kassuha, Walter Manucha
Cardiovascular diseases are a major cause of disability and they are currently responsible for a significant number of deaths in a large percentage of the world population. A large number of therapeutic options have been developed for the management of cardiovascular diseases. However, they are insufficient to stop or significantly reduce the progression of these diseases, and may produce unpleasant side effects. In this situation, the need arises to continue exploring new technologies and strategies in order to overcome the disadvantages and limitations of conventional therapeutic options...
February 1, 2017: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/28164744/thrombolysis-in-peripheral-artery-disease
#2
Sotirios Giannakakis, George Galyfos, Ioannis Sachmpazidis, Kostas Kapasas, Stavros Kerasidis, Ioannis Stamatatos, Georgios Geropapas, Georgios Kastrisios, Gerasimos Papacharalampous, Chrisostomos Maltezos
Peripheral artery disease (PAD) has been associated with severe morbidity and mortality worldwide, affecting the quality of life for millions of patients. Acute thrombosis has been identified as a major complication of PAD, with proper management including both open as well as endovascular techniques. Thrombolysis has emerged as a reasonable option in the last decades to treat such patients although data produced by randomized trials have been limited. This review aims to present major aspects of thrombolysis in PAD regarding its indications and contraindications, technique tips as well as to review literature data in order to produce useful conclusions for everyday clinical practice...
February 1, 2017: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/28190378/overview-of-the-non-vitamin-k-oral-anticoagulants-for-atrial-fibrillation
#3
Robert P Giugliano
No abstract text is available yet for this article.
March 2017: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/28033742/assessment-of-achieved-systolic-blood-pressure-in-newly-treated-hypertensive-patients-aged-60-79-years-before-and-after-eighth-joint-national-committee-recommendations
#4
Michael S Kelly, Joseph J Saseen, Joel C Marrs
OBJECTIVE: To determine whether patients who were newly prescribed antihypertensive therapy after the Eighth Joint National Committee (JNC 8) update were treated to a relaxed systolic blood pressure (SBP) goal compared with patients treated before the update. METHODS: A retrospective cohort study approved by the Colorado Multiple Institutional Review Board. Patients aged 60-79 years, without diabetes or chronic kidney disease (CKD), newly treated for hypertension at a University of Colorado primary care clinics were included...
February 2017: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/27932570/effect-of-losartan-combined-with-amlodipine-or-with-a-thiazide-on-uric-acid-levels-in-hypertensive-patients
#5
Alberto F Rubio-Guerra, Ana K Garro-Almendaro, Cesar I Elizalde-Barrera, Juan A Suarez-Cuenca, Montserrat B Duran-Salgado
Hyperuricemia leads to endothelial dysfunction and insulin resistance, and has been associated with diseases such as hypertension. Antihypertensive drugs modify serum uric acid levels, however, few data are available about their combinations on uricemia. In this study we evaluate the effect of two combinations of losartan, with amlodipine or with hydrochlorothiazide, on serum uric acid levels in hypertensive patients. METHODS: A total of 60 hypertensive patients were randomized in two groups; group LA received losartan/amlodipine (100/5 mg) once a day, whereas LH group received losartan hydrochlorothiazide (100/12...
February 2017: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/27884949/control-of-blood-pressure-and-cardiovascular-risk-in-moroccan-patients-with-newly-diagnosed-hypertension-a-3-month-observational-study-in-primary-care
#6
Mohamed Alami, Mustapha El Hattaoui, Mehdi Seqat, Jamaa Sadik, Aicha Aouad, Mohammed Benghanem Gharbi
BACKGROUND: Control of blood pressure and reduction of cardiovascular risk factors are mandatory in patients with hypertension. The aim of this study was to determine the proportion of patients with controlled hypertension and to describe the cardiovascular risk profile in hypertensive patients followed by general practitioners (GPs) in Morocco. METHODS: This national, observational, multicentre, prospective, longitudinal study of patients with newly diagnosed hypertension was carried out between September 2011 and December 2011...
February 2017: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/27659287/emerging-role-of-ivabradine-for-rate-control-in-atrial-fibrillation
#7
REVIEW
Sarah L Turley, Kerry E Francis, Denise K Lowe, William D Cahoon
Control of ventricular rate is recommended for patients with paroxysmal, persistent, or permanent atrial fibrillation (AF). Existing rate-control options, including beta-blockers, nondihydropyridine calcium channel blockers, and digoxin, are limited by adverse hemodynamic effects and their ability to attain target heart rate (HR). Ivabradine, a novel HR-controlling agent, decreases HR through deceleration of conduction through If ('funny') channels, and is approved for HR reduction in heart failure patients with ejection fraction less than 35% and elevated HR, despite optimal pharmacological treatment...
December 2016: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/27587602/diuretics-prevent-rho-kinase-activation-and-expression-of-profibrotic-oxidative-genes-in-the-hypertensive-aortic-wall
#8
Patricio Araos, David Mondaca, Jorge E Jalil, Cristián Yañez, Ulises Novoa, Italo Mora, María Paz Ocaranza
BACKGROUND: Diuretics are current antihypertensive drugs since they reduce blood pressure and cardiovascular risk. Increased vascular tone is modulated in a relevant way by the RhoA/Rho-kinase (ROCK) pathway, by acting on vascular smooth muscle cell contraction. This pathway has also proremodeling vascular effects. There are few data on the role of diuretics on both vascular ROCK activation and on proremodeling effects. We assessed the effects of hydrochlorothiazide (HCTZ) and spironolactone (spiro) alone and in combination with the ROCK inhibitor fasudil (FAS) on ROCK activation, gene expression of proremodeling markers and on hypertrophy in the aortic wall of hypertensive rats...
December 2016: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/26944072/blood-pressure-treatment-goals-in-hypertension
#9
EDITORIAL
Rainer Düsing
No abstract text is available yet for this article.
December 2016: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/27784812/the-protective-role-of-vitamin-d-on-the-heart-and-the-kidney
#10
REVIEW
Walter Manucha, Luis I Juncos
For a long time, vitamin D was regarded as an essential component for the maintenance of appropriate calcium metabolism. Indeed, the calcium-related functions were broadly studied and validated in numerous clinical and epidemiologic studies. All of these vitamin D effects are mediated by a specific receptor. Remarkably, recent investigations show that the vitamin D receptor (VDR) also affects autoimmunity and by these means, the course of neoplasias and tissue inflammation. Moreover, the VDR regulates genes that affect cellular activity including cell differentiation and apoptosis and, by these means, angiogenesis...
October 26, 2016: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/27765885/novel-oral-anticoagulants-for-acute-coronary-syndrome
#11
REVIEW
April Robinson, Delilah McCarty, Janine Douglas
Acute coronary syndrome (ACS) is a cardiovascular condition with a multifactorial pathophysiology that includes atherosclerotic plaques, platelet activation and thrombin production, among others. Thrombin production and the prothrombotic state of ACS patients have provided a role for anticoagulants to treat patients during the acute event and has led to subsequent research for the post-acute state. Warfarin has an indication for ACS, however, it is restricted to specific patients and many factors limit its use...
October 7, 2016: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/27378486/surrogate-and-clinical-endpoints-in-interventional-cardiology-are-statistics-the-brakes
#12
REVIEW
Matthias Waliszewski, Harald Rittger
BACKGROUND: Randomized controlled trials are the gold standard for demonstrating safety and efficacy of coronary devices with or without accompanying drug treatments in interventional cardiology. With the advent of last-generation drug-eluting stents having enhanced technical attributes and long-term clinical benefits, the proof of incremental angiographic or long-term clinical efficacy becomes more challenging. The purpose of this review is to provide an overview of the most common and alternative study endpoints in interventional cardiology and their potential reimbursement value...
October 2016: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/27122492/aldosterone-is-associated-with-left-ventricular-hypertrophy-in-hemodialysis-patients
#13
REVIEW
Greicy Mara Mengue Feniman De Stefano, Silméia Garcia Zanati-Basan, Laercio Martins De Stefano, Viviana Rugolo Oliveira E Silva, Patrícia Santi Xavier, Pasqual Barretti, Roberto Jorge da Silva Franco, Jacqueline Costa Teixeira Caramori, Luis Cuadrado Martin
OBJECTIVES: Patients with chronic kidney disease present a higher degree of left ventricular hypertrophy than expected for hypertension levels. In chronic kidney disease the plot between the quotient extracellular water/total body water and aldosterone is shifted up and to the right. There are few studies that verified the role of aldosterone in cardiac remodeling in this set of patients. The aim of this study was to evaluate the relationship between serum aldosterone and left ventricular mass index in patients with chronic kidney disease on hemodialysis...
October 2016: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/27090286/management-of-rivaroxaban-in-relation-to-bodyweight-and-body-mass-index
#14
REVIEW
James Uprichard
Being overweight or obese is associated with a higher individual risk of venous thromboembolism and poorer postprocedural outcomes after hip or knee replacement surgery. In addition, there is evidence that obesity represents a significant driving factor for the current and projected prevalence of atrial fibrillation. Rivaroxaban and other direct oral anticoagulants offer fixed-dose regimens for these indications. They do not require therapeutic drug monitoring or dose adjustment according to the weight of the patient...
October 2016: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/26755746/the-emerging-role-of-endothelin-1-in-the-pathogenesis-of-pre-eclampsia
#15
REVIEW
Langeza Saleh, Koen Verdonk, Willy Visser, Anton H van den Meiracker, A H Jan Danser
Pre-eclampsia (PE) is the most frequently encountered medical complication during pregnancy. It is characterized by a rise in systemic vascular resistance with a relatively low cardiac output and hypovolemia, combined with severe proteinuria. Despite the hypovolemia, renin-angiotensin system (RAS) activity is suppressed and aldosterone levels are decreased to the same degree as renin. This suggests that the RAS is not the cause of the hypertension in PE, but rather that its suppression is the consequence of the rise in blood pressure...
October 2016: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/27555569/primary-and-key-secondary-results-from-the-rocket-af-trial-and-their-implications-on-clinical-practice
#16
REVIEW
Rohan Shah, Manesh R Patel
BACKGROUND: The safety and efficacy of the oral anticoagulant rivaroxaban were studied in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF trial). A number of subanalyses of the ROCKET AF trial have subsequently analyzed the use of rivaroxaban in special patient populations. METHODS: The outcomes of the ROCKET AF trial were reviewed. The use of rivaroxaban in higher risk populations, as determined by the presence of co-morbidities included in the CHADS2 criteria, was analyzed...
August 23, 2016: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/27215618/nitric-oxide-in-paediatric-respiratory-disorders-novel-interventions-to-address-associated-vascular-phenomena
#17
REVIEW
Farhana Akter, Gerry Coghlan, Achala de Mel
Nitric oxide (NO) has a significant role in modulating the respiratory system and is being exploited therapeutically. Neonatal respiratory failure can affect around 2% of all live births and is responsible for over one third of all neonatal mortality. Current treatment method with inhaled NO (iNO) has demonstrated great benefits to patients with persistent pulmonary hypertension, bronchopulmonary dysplasia and neonatal respiratory distress syndrome. However, it is not without its drawbacks, which include the need for patients to be attached to mechanical ventilators...
August 2016: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/27099243/new-onset-lone-atrial-fibrillation-in-pregnancy
#18
LETTER
Viswajit Reddy Anugu, Nikhil Nalluri, Deepak Asti, Sainath Gaddam, Thomas Vazzana, James Lafferty
No abstract text is available yet for this article.
August 2016: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/27099242/efficacy-of-topical-local-anaesthesia-to-reduce-perioperative-pain-for-endovenous-laser-ablation-of-varicose-veins-a-double-blind-randomized-controlled-trial
#19
Sunita Saha, Alok Tiwari, Charlotte Hunns, Jonathan Refson, Ahmed Abidia
OBJECTIVES: Tumescent local anaesthesia via multiple injections in the perivenous space leads to intraoperative and postoperative pain during endovenous laser ablation (EVLA). We considered whether the application of topical local anaesthesia reduces pain caused by these injections. METHODS: Eligible patients undergoing local anaesthetic EVLA were recruited and randomized to either application of topical local anaesthesia or water-based gel (placebo) to the inner thigh over the marked great saphenous vein...
August 2016: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/27060185/validated-formulae-for-estimation-of-whole-blood-viscosity-underestimate-the-influence-of-erythrocyte-aggregation-and-deformability
#20
LETTER
Joseph Weidman, Gregory Sloop, John A St Cyr
No abstract text is available yet for this article.
August 2016: Therapeutic Advances in Cardiovascular Disease
journal
journal
41744
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"